Press Room

Digital RDD 2020

Start
Sunday, April 26, 2020 - 00:00
End
Tuesday, June 30, 2020 - 00:00
Location: online

RDD 2020 and IPAC-RS in Desert Springs, California, April 26-May 1, 2020 are canceled. The organization is holding the Digital RDD 2020.

 

Digital RDD 2020 is open 24/7 until June 30

 

HOVIONE DIGITAL PRESENTATION:

  • Title: “Spray Dried Particles for Inhalation: Process Development Following a QbD Approach”

    João Henriques, PhD, Hovione, Lisbon, Portugal

 

HOVIONE DIGITAL POSTER:

  • Title: “Spray-dried Microparticles vs. Chimeral Agglomerates for Nasal Powder Delivery: Characterization and Aerodynamic Performance"

    Patricia Henriques, PhD Student, R&D DPD, Hovione, Lisbon, Portugal

 

 

If you would like to find more about Hovione's full range of inhalation development servicesparticle engineering and development by design schedule a meeting with us.

Schedule a meeting button | Hovione

Our colleague Steve Landelius will be pleased to meet you.

steve-landelius-photo

Steven Landelius

Business Development Manager
 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026